Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative endocrine treatment with letrozole ± triptorelin in ER/PgR-positive locally advanced breast cancer
2007-006026-10Phase 2Completed
- Sponsor
- European Institute of Oncology
- Start
- Feb 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of letrozole and triptorelin in breast cancer (2 arms), sponsored by European Institute of Oncology. Primary endpoints: Objective clinical response rate at 6 months, Objective clinical response rate at 9 months and 1 more. Started Feb 2008; status: completed.
02
Drugs
letrozoletriptorelin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2007-006026-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006026-10.